| Press Release Source: Sanofi (EURONEXT: SAN) (NYSE: SNY) | ||
| Sanofi Head of Global R&D Elias Zerhouni to retire; Company names John Reed to take over on July 1 Paris - 24th April 2018 -- Elias Zerhouni, M.D., Head of Global Research and Development will retire from Sanofi on June 30th, 2018, after more than 9 years of distinguished service with the company. He will be succeeded in the post by John C. Reed, M.D. Ph.D. who has been appointed Head of Global Research & Development, as of July 1st, 2018. Dr. Zerhouni joined Sanofi in 2009 as scientific advisor to the Chief Executive Officer and was appointed to his current post in January 2011. "Throughout his tenure at Sanofi, Elias has relentlessly and passionately strived to transform Sanofi R&D into an organization with the potential to be one of the very best in the industry. We are grateful for his outstanding contributions to Sanofi and wishing him all the best for the future," said Sanofi Chief Executive Officer Olivier Brandicourt, M.D. Appointment of John C. Reed Dr. Reed will report directly to Dr. Brandicourt and will be a member of the Executive Committee. He will join Sanofi on April 30th to ensure a smooth and effective transition period. "John is an accomplished and widely recognized physician-scientist with a brilliant academic track record," said Dr. Brandicourt. "He is experienced in driving R&D productivity, building high-performing teams and integrating biotech companies to provide new technology platforms." For the past five years Dr. Reed has served as the Global Head of Roche Pharma Research & Early Development (pRED), responsible for directing research and early development activities through Phase 2b proof-of-concept (PoC) across all therapeutic areas, including oncology, immunology, rare diseases, neuroscience, ophthalmology and infectious diseases. He was also a member of Roche's Corporate Executive Committee, reporting to the CEO. Dr. Reed holds a B.A in chemistry from the University of Virginia, Charlottesville and a M.D. PhD. from the University of Pennsylvania, School of Medicine where he began his academic career at the University in 1988, following a post-doctoral fellowship in Molecular Biology at the Wistar Institute and a residency in Pathology & Laboratory Medicine at Hospital of University Pennsylvania. He then joined the Burnham Institute in 1992, one of the best known biomedical research institutes in the U.S, where he held multiple positions of increasing responsibility such as Program Director of the NCI-designated Cancer Center, Scientific Director, and Director of the Cancer Center. In 2002 he was appointed President and CEO of the Sanford-Burnham Medical Research Institute. | ||
| About Sanofi Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe. Sanofi, Empowering Life | ||
| Media Relations Contacts Jack Cox Tel.: +33 (0)1 53 77 46 46 [email protected] Ashleigh Koss (United States) Tel.: +1 (908) 205-2572 [email protected] | Investor Relations Contact George Grofik Tel.: +33 (0)1 53 77 45 45 [email protected] | |
Attachment


BlueScope Steel Forecasts Stronger Second-Half Earnings, Shares Rise Above Rejected Buyout Offer
Anduril Eyes $60 Billion Valuation in New Funding Round to Expand Defense Manufacturing and Autonomous Fighter Jet Development
Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease
Vietnam Approves SpaceX Starlink Satellite Internet Service Amid U.S. Trade Talks
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings
OpenAI Hires OpenClaw Creator Peter Steinberger to Advance Next-Generation AI Agents
GE Aerospace Expands Singapore Engine Repair Hub with Automation and AI to Tackle Aviation Bottlenecks
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions
Bank of America CEO Brian Moynihan’s 2025 Compensation Rises 17% to $41 Million Amid Strong Profit Growth
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase
Sachem Head Boosts Warner Bros. Discovery Stake Amid Netflix Deal and Paramount Bid
How Marco Pharma International Preserves German Homeopathic Traditions in America
Disney Issues Cease-and-Desist to ByteDance Over Alleged AI Copyright Infringement
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth
Mitsui Kinzoku Stock Surges to Record High After Profit Forecast Upgrade and Dividend Increase 



